Sep 19, 2016
The campaign to achieve greater transparency in clinical research activity regulated or funded by the federal government, including the results of those studies, is moving forward after months of debate.
Sep 18, 2016
Concerns have emerged that continued growth in biosimilars could be limited by mounting pressure to push down on prescription drug outlays. Jill Wechsler reports.
Aug 30, 2016
The outrage over Mylan’s price hikes for its EpiPen auto-injector illustrates the many factors that keep drug pricing immune from normal economic pressures, writes Jill Wechsler.
Aug 30, 2016
$7.5 billion in pharma “transfers of value” made in 2015 has caught the attention of the DoJ and federal/state prosecutors investigating fraud. Jill Weschler reports.
Aug 24, 2016
Traditional sales and pricing practices face legal challenges and political backlash, writes Jill Wechsler.
Aug 15, 2016
Reflector outlines the obstacles ahead for Europe's revamped Innovative Medicines Initiative.
Aug 12, 2016
Zika vaccine development is hindered by technical challenges and funding shortfalls, writes Jill Wechsler.
Aug 12, 2016
Pharmaceutical Executive
Analysts examine investment and business factors that shape supply disruptions. Jill Wechsler reports.
Aug 08, 2016
Could the new Vermont Drug Transparency law “lead the US Pharmaceutical industry to an awful end”? Tom Norton reports.
Aug 05, 2016
Having lobbied hard to have Inter Partes Review proceedings (IPRs) enacted, the tech industry may now be regretting what it wished for, write Traci Medford-Rosow and Peter C. Richardson.
lorem ipsum